The Bethesda System (TBS)
The unified international terminology system for reporting cervical cytology in cervical cancer screening and diagnosis (TBS 2014).
System Definition
The Bethesda System (TBS) — is a standardized system for reporting cervical cytology findings. Originally developed in 1988 at a National Cancer Institute (NCI) workshop in Bethesda, Maryland, revised in 1991 and 2001, with the current standard being TBS 2014 (3rd Edition).
The system replaced fragmented classifications (Papanicolaou classes, CIN, dysplasia) with a uniform communication language between pathologists and clinicians, ensuring reproducible patient management.
Core Principles
Unambiguity
Diagnostic reports are interpreted unambiguously by gynecologists, oncologists, and pathologists.
Reproducibility
Inter-laboratory consistency ensuring identical morphology is classified under standardized categories.
Clinical Relevance
Continuously harmonized with HPV molecular biology, liquid-based cytology, and vaccination data.
Bethesda Categories
From normal epithelium to invasive carcinoma
Negative for Intraepithelial Lesion or Malignancy
No cellular evidence of neoplasia or intraepithelial lesion. May show reactive cellular changes, atrophy, or benign infectious organisms.
Atypical Squamous Cells of Undetermined Significance
Atypical squamous cells of undetermined significance. Cytologic changes suggestive of SIL but lacking definitive criteria. Reflex HPV DNA testing is standard triage.
Atypical Squamous Cells, cannot exclude HSIL
Atypical squamous cells cannot exclude high-grade squamous lesion. Risk of underlying CIN 2/3 up to 40%. Direct colposcopy is mandatory.
Low-grade Squamous Intraepithelial Lesion
Low-grade squamous intraepithelial lesion encompassing transient HPV cytopathic effect (koilocytosis) and CIN 1. High spontaneous regression rate in young women.
High-grade Squamous Intraepithelial Lesion
High-grade squamous intraepithelial lesion encompassing CIN 2, CIN 3, and carcinoma in situ. High risk of progression to invasive cancer. Immediate colposcopy required.
Atypical Glandular Cells
Atypical glandular cells (endocervical, endometrial, or not otherwise specified). Associated with serious neoplasia; requires colposcopy, endocervical sampling, and endometrial biopsy if indicated.
Adenocarcinoma in situ
Endocervical adenocarcinoma in situ. Definitive pre-invasive glandular neoplasia requiring diagnostic and therapeutic excisional procedure with clear margins.
Squamous Cell Carcinoma
Invasive squamous cell carcinoma. Immediate referral to gynecologic oncology for histologic verification, colposcopy/biopsy, and clinical staging.
Clinical Significance
Common Language
Standardized terminology uniformly understood by gynecologists and oncologists.
Data Comparability
Standardization allows robust national screening audits and registry comparability.
Management Continuity
Each cytologic threshold maps directly to risk-based ASCCP colposcopy referral algorithms.
Clinical Vault Protocols
Full-text colposcopy guidelines and evidence-based protocols are available in Member Portal.